Zhang Wei-Tao, Wang Ya-Fei
Department of Neurosurgery, The People's Hospital of Yan'an, Yan'an Department of Neurosurgery, The People's Hospital of Ningxia, Yinchuan, China.
Medicine (Baltimore). 2017 Jun;96(25):e6960. doi: 10.1097/MD.0000000000006960.
This study aimed to evaluate the effect of methylphenidate for treating mental sequelae after traumatic brain injury (TBI).
Thirty-six patients with TBI were randomly divided into the intervention group and placebo group. The participants in the intervention group received methylphenidate, while subjects in the placebo group were administered a placebo. This study was conducted from January 2014 to December 2016. The outcome measurements included Mental Fatigue Scale, Choice Reaction Time, Compensatory Tracking Task, Mental Arithmetic Test, Digit Symbol Substitution Test, Mini-Mental State Examination (MMSE), Beck Depression Inventory (BDI), and Hamilton Rating Scale for Depression. In addition, safety was also recorded and assessed.
A total of 33 subjects completed the study. Methylphenidate showed greater efficacy than placebo, with decreased scores on the Mental Fatigue Scale, Choice Reaction Time, and Compensatory Tracking Task in the intervention group compared to the placebo group (P < .01, respectively). Furthermore, increased scores on the Mental Arithmetic Test, Digit Symbol Substitution Test, and MMSE in the intervention group, compared to those in the placebo group (P < .01 respectively), were observed. In addition, a significant difference in the scores on the BDI (P = .04) and Hamilton Rating Scale for Depression (P = .005) was observed between the 2 groups. The safety at the end of the 30 week-treatment was similar between the 2 groups (P > .05).
The results of this study demonstrated that methylphenidate could effectively improve mental fatigue and cognitive functions in patients with TBI.
本研究旨在评估哌甲酯治疗创伤性脑损伤（TBI）后精神后遗症的效果。
36例TBI患者被随机分为干预组和安慰剂组。干预组参与者接受哌甲酯治疗，而安慰剂组受试者服用安慰剂。本研究于2014年1月至2016年12月进行。结局测量包括精神疲劳量表、选择反应时、补偿跟踪任务、心算测试、数字符号替换测试、简易精神状态检查表（MMSE）、贝克抑郁量表（BDI）和汉密尔顿抑郁评定量表。此外，还记录并评估了安全性。
共有33名受试者完成了研究。哌甲酯显示出比安慰剂更高的疗效，与安慰剂组相比，干预组的精神疲劳量表、选择反应时和补偿跟踪任务得分降低（分别为P<0.01）。此外，与安慰剂组相比，干预组在心算测试、数字符号替换测试和MMSE中的得分增加（分别为P<0.01）。此外，两组在BDI得分（P=0.04）和汉密尔顿抑郁评定量表得分（P=0.005）上存在显著差异。两组在30周治疗结束时的安全性相似（P>0.05）。
本研究结果表明，哌甲酯可有效改善TBI患者的精神疲劳和认知功能。
